A call for the creation of personalized medicine databases
- 23 December 2005
- journal article
- opinion
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (1) , 23-26
- https://doi.org/10.1038/nrd1931
Abstract
The success of the Human Genome Project raised expectations that the knowledge gained would lead to improved insight into human health and disease, identification of new drug targets and, eventually, a breakthrough in healthcare management. However, the realization of these expectations has been hampered by the lack of essential data on genotype–drug-response phenotype associations. We therefore propose a follow-up to the Human Genome Project: forming global consortia devoted to archiving and analysing group and individual patient data on associations between genotypes and drug-response phenotypes. Here, we discuss the rationale for such personalized medicine databases, and the key practical and ethical issues that need to be addressed in their establishment.Keywords
This publication has 30 references indexed in Scilit:
- Drug safety and regulationBMJ, 2005
- Pharmacogenetics: ethical problems and solutionsNature Reviews Genetics, 2004
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- GlaxoSmithKline to publish clinical trials after US lawsuitBMJ, 2004
- An “Omics” view of drug developmentDrug Development Research, 2004
- Readmissions and adverse drug reactions in internal medicine: the economic impactJournal of Internal Medicine, 2004
- PharmGKB: the pharmacogenetics and pharmacogenomics knowledge baseThe Pharmacogenomics Journal, 2004
- Editorial: Building successful biological databasesBriefings in Bioinformatics, 2004
- A vision for the future of genomics researchNature, 2003
- Should Third-World countries pay the tab for new drug development?Academic Medicine, 1999